Patent: 7,927,836

Summary for Patent: 7,927,836

Patent Claims:

see list of patent claims

Scope and claims summary:

United States Patent 7927836, titled "Method and system for generating, displaying, and manipulating in vivo models of vascular tissue," was filed on February 2, 2009, by Bruce V. R. Russell of Massachusetts General Hospital and assigned to Brigham and Women's Hospital. The patent issued on May 19, 2011. Scope of the Patent This patent covers a method and system for generating, displaying, and manipulating in vivo models of vascular tissue using fluorescent liposomes. The liposomes are designed to target certain cell types within the vascular tissue, injectable, and emit a fluorescent signal when excited by a laser. This allows researchers to visualize and track specific cellular structures and pathways in real-time. Key Claims The patent claims are broadly categorized into several aspects of the invention: Methods: The patent claims several methods for generating, displaying, and manipulating fluorescent liposomes in vivo. These include methods for creating liposomes, incorporating fluorescent dyes, targeting specific cell types, and adjusting the liposome's emission wavelength. Apparatus: The patent claims an apparatus for generating and injecting the liposomes, comprising a fluorescence labeling system, an ultrasound system for targeting, and a micromanipulation system for tracking the liposomes. Components: The patent claims several components of the system, including the fluorescent liposomes, the fluorescence labeling system, the ultrasound system, and the micromanipulation system. Applications: The patent claims broad applications for the invention, including in vivo high-resolution imaging and super-resolution imaging using optical and ultrastructural methods. Key Findings and Significance The patent highlights several potential benefits and applications of the invention, including: In vivo imaging: The fluorescent liposomes enable high-resolution imaging of vascular tissue in real-time, providing valuable insights into vascular pathophysiology and disease. Super-resolution imaging: The invention enables the use of optical and ultrastructural methods to achieve super-resolution imaging of vascular tissue, exceeding the diffraction limit of traditional microscopes. Targeted manipulation: The patent claims methods for targeting specific cell types within the vascular tissue, potentially opening new avenues for therapeutic applications. Implications and Impact This patent impacts the field of biopharmaceutical research, particularly in the areas of cardiovascular and vascular biology. By providing a novel system for visualizing and manipulating vascular tissue in vivo, the invention has the potential to: Revolutionize vascular imaging: The fluorescent liposomes and associated systems enable high-resolution imaging of vascular tissue, potentially leading to more accurate diagnoses and treatments of vascular diseases. Enable new therapeutic applications: The targeted manipulation capabilities of the invention may lead to new therapeutic strategies for addressing vascular diseases, such as plaque buildup and aneurysm formation. Limitations and Challenges While the patent has several potential benefits, it also presents some limitations and challenges, including: Technical complexity: The invention involves complex systems and techniques, requiring specialized expertise and equipment. Safety and efficacy: The safety and efficacy of the fluorescent liposomes and associated systems need to be thoroughly evaluated before they can be used in clinical applications. In this analysis, we have explored the scope and claims of United States Patent 7927836, covering a method and system for generating, displaying, and manipulating in vivo models of vascular tissue using fluorescent liposomes. The patent has the potential to impact the field of biopharmaceutical research, particularly in the areas of cardiovascular and vascular biology.

Details for Patent 7,927,836

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	July 30, 2010
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	November 20, 2015